CTRI/2021/08/035346Other未知
A randomised, single dose, open label, three-period, cross-over, comparative bioavailability study between the test product, Remdesivir oral solution 100 mg/5 mL (Cipla Ltd., India) and the reference product, CIPREMI (Lyophilised) Remdesivir for injection 100 mg/ vial) (Cipla Ltd., India) in healthy adult male human subjects under fasting conditions. - 21-04-099
Cipla Ltd India0 个研究点目标入组 16 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- Other
- 发起方
- 入组人数
- 16
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •1.Volunteers who give consent by signing the informed consent form after understanding the study related information about the nature, risk, and scope of the clinical study as well as the expected adverse effects of the drug.
- •2.Volunteers who are healthy adult between 18 to 45 years of age (both inclusive) of Asian Indian origin.
- •3.Volunteers who have a Body Mass Index between 18.5 and 30 kg/m2, weighing not less than 45 kg.
- •4.Volunteers who have no evidence of any significant diseases or clinically significant abnormal findings during the pre-study screening, medical and medication histories, vital signs examination, physical examination, 12-lead electrocardiogram (ECG) and chest X-ray (postero-anterior view recorded in last 180 days).
- •5.Volunteers, whose urine alcohol test and urine test for drugs of abuse are negative and whose Rapid Plasma Reagin (RPR), Hepatitis B Surface Antigen (HBsAg), Hepatitis C (Anti HCV) and antibodies to human immuno-deficiency Virus (HIV) I and II are negative or non-reactive.
- •6.Volunteers whose pre-study screening laboratory tests are within normal limit or clinically not significant.
- •7.Volunteers who have agreed to follow the appropriate distancing, all the necessary safety precautions like wearing mask, using hand sanitizer etc. during the study.
- •8.Volunteers who agree to abstain from consuming grapefruit or its products for at least 72 hours prior to dosing and until the last blood sample collection of each study period.
- •9.Volunteers who agree to abstain from consuming citrus fruits or their products and xanthine containing products (chocolate, tea, coffee or cola drink), for at least 24 hours prior to dosing and until the last blood sample collection of each study period.
- •10.Volunteers who do not have history of drug addiction or a habit of heavy drinking which is defined as regular intake of more than 2 units of alcohol per day for males (1 unit is equal to 150 mL of wine or 360 mL of beer or 45 mL of 40 percent alcohol) and those who agree to abstain from consuming alcohol or alcoholic products for at least 48 hours prior to dosing and until the last blood sample collection of each study period.
- •11.Volunteers who are non-smokers or those who are ex-smokers and have less than a 10 pack-year history of smoking and have not consumed tobacco or tobacco containing products for at least 12 months prior to screening and who agree to abstain from the same until the last blood sample collection of the last treatment period.
- •12.Volunteers must agree to be available for the entire study and have the ability to understand and communicate effectively with the investigators and study personnel.
- •13.Volunteers whose test for COVID-19 is negative
排除标准
- •1.Volunteers who have history of known hypersensitivity to Remdesivir or related class of drug.
- •2.Volunteers with history of a known food allergy.
- •3.Volunteers who have vital signs abnormalities (systolic blood pressure less than 100 or greater than 140 mm of Hg or diastolic blood pressure less than 60 or greater than 90 mm of Hg or pulse rate less than 50 beats per minute or more than 100 beats per minute) during pre-study screening and vital signs examination before check-in.
- •4.Volunteers having any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract.
- •5.Volunteers who have recent history of dehydration from diarrhoea, vomiting or any other reason within a period of 24 hours prior to the study check-in.
- •6.Volunteers having Estimated Glomerular Filtration Rate (eGFR) less than 60 mL/min/1.73 m2 calculated by MDRD (Modification of Diet in Renal Disease Study) formula.
- •7.Volunteers who have clinically significant signs and symptoms or history of respiratory, cardiovascular, gastrointestinal, dermatological, neurological, psychiatric, genitourinary, endocrinological, musculoskeletal, bleeding disorder, tumor/ cancer, eye, ear, nose and throat disease.
- •8.Volunteer with febrile illness within 1 week before start of the study.
- •9.Volunteers who have suffered any clinically significant illness in the 2 weeks prior to dosing or who have been hospitalised within 3 months preceding the start of the study.
- •10.Volunteers who have taken any drug that induces/inhibits the hepatic microsomal enzymes (including chloroquine phosphate and hydroxychloroquine sulfate) within 30 days prior to dosing.
- •11.Volunteers who have taken any prescription medication or over-the-counter products available (including vitamins and products from natural origin such as ayurvedic, unani, siddha and homeopathic medicines) and topical medication meant for systemic absorption, within the 7 days prior to dosing.
- •12.Volunteers who have depot injection or an implant of any drug within 3 months prior to dosing.
- •13.Volunteers who have a history of difficulty in donating blood.
- •14.Volunteers who have donated blood (1 unit or 350 mL) within 90 days prior to dosing.
- •15.Volunteers who have taken any investigational product or participated in any drug research study requiring blood donation within 90 days prior to dosing.
- •16.Volunteers who have unsuitable veins for repeated venepuncture, evidence of skin lesions on forearm or signs of venepuncture on the forearm suggestive of recent blood donation or participation in a study.
研究者
相似试验
已完成
不适用
A study to compare the pharmacokinetics and safety/tolerability of BS-105 enteric-coated tablet A” or BS-105 enteric-coated tablet B” of Bio-Synectics to original drug in healthy male subjects (Pilot study)Certain infectious and parasitic diseasesKCT0004007Bio-Synectics9
已完成
不适用
A clinical study to compare pharmacokinectic characteristics of Eperisone Hydrochloride and Aceclofenac with HCP1104 treatment to those of co-administration of Eperisone Hydrochloride 50mg tablet and Aceclofenac 100mg tablet in healthy adult male volunteersKCT0000907Hanmi Pharm30
招募中
不适用
A randomized, open-label, single dose, 3-treatment, 3-period, 6-sequence crossover study to investigate the effect of food on the pharmacokinetics/pharmacodynamics and safety of CKD-519 after oral administration in healthy adult volunteersEndocrine, nutritional and metabolic diseaseKCT0001545Chong Kun Dang42
招募中
不适用
Relative bioavailability of montelukast sodium 5mg from two candidate chewable tablet formulations of GW483100 relative to one 5mg chewable tablet of reference montelukast sodium in healthy adult subjects under fasting conditionsCTRI/2015/03/005625GlaxoSmithKline Research and Development Limited18
已完成
不适用
Relative bioavailability study of two candidate formulations of GR107719B (Mosapride 5 mg) under fasting conditionsCTRI/2014/01/004318GlaxoSmithKline Research and Development Limited18